Abstract
Evidence on the effects of hormonal contraceptives on female sexuality is conflicting. We enrolled 556 women, divided into six groups: two composed of subjects using a combined hormonal contraceptive (COC) containing 0.020 ("COC20") and 0.030 ("COC30") mg of ethynyl estradiol (EE), "natural", using COC containing 1.5 mg of estradiol (E2), "ring", using a vaginal ring releasing each day 0.015 mg of EE + 0.120 of etonogestrel, "subcutaneous", using a progestin only subcutaneous contraceptive implant releasing etonogestrel and "controls", using no hormonal contraceptive methods. The subjects were required to answer to the McCoy female sexuality questionnaire and were subjected to a blood test for hormonal evaluation. An ultrasound evaluation of the dorsal clitoral artery was also performed. The higher McCoy sexological value were recorded in the subdermal group; significant differences were recorded among the groups in terms of hormone distribution, with the higher levels of androstenedione in subdermal and control groups. The ultrasound evaluation of dorsal clitoral artery shows a significative correlation between pulsatility and resistance indices and orgasm parameters of McCoy questionnaire. The recorded difference in the sexual and hormonal parameters among the studied hormonal contraceptives may guide toward the personalization of contraceptive choice.
Keywords:
Combined hormonal contraceptive; McCoy female sexuality questionnaire; dorsal clitoral artery ultrasound; hormonal profile; personalized contraception.
MeSH terms
-
Adult
-
Clitoris / blood supply
-
Clitoris / diagnostic imaging
-
Clitoris / drug effects
-
Contraceptive Agents, Female / administration & dosage*
-
Contraceptive Agents, Female / adverse effects
-
Contraceptive Agents, Female / blood
-
Contraceptive Agents, Female / pharmacokinetics
-
Contraceptive Devices, Female* / adverse effects
-
Contraceptives, Oral, Combined / administration & dosage*
-
Contraceptives, Oral, Combined / adverse effects
-
Contraceptives, Oral, Combined / blood
-
Contraceptives, Oral, Combined / pharmacokinetics
-
Contraceptives, Oral, Hormonal / administration & dosage*
-
Contraceptives, Oral, Hormonal / adverse effects
-
Contraceptives, Oral, Hormonal / blood
-
Contraceptives, Oral, Hormonal / pharmacokinetics
-
Delayed-Action Preparations / administration & dosage
-
Delayed-Action Preparations / adverse effects
-
Desogestrel / administration & dosage
-
Desogestrel / adverse effects
-
Desogestrel / blood
-
Desogestrel / pharmacokinetics
-
Dose-Response Relationship, Drug
-
Drug Implants
-
Estrogens / administration & dosage*
-
Estrogens / adverse effects
-
Estrogens / blood
-
Estrogens / pharmacokinetics
-
Female
-
Humans
-
Italy
-
Megestrol / administration & dosage
-
Megestrol / adverse effects
-
Megestrol / blood
-
Megestrol / pharmacokinetics
-
Norpregnadienes / administration & dosage
-
Norpregnadienes / adverse effects
-
Norpregnadienes / blood
-
Norpregnadienes / pharmacokinetics
-
Orgasm / drug effects
-
Progestins / administration & dosage*
-
Progestins / adverse effects
-
Progestins / blood
-
Progestins / pharmacokinetics
-
Regional Blood Flow / drug effects
-
Self Report
-
Sexual Behavior / drug effects*
-
Ultrasonography, Doppler
-
Young Adult
Substances
-
Contraceptive Agents, Female
-
Contraceptives, Oral, Combined
-
Contraceptives, Oral, Hormonal
-
Delayed-Action Preparations
-
Drug Implants
-
Estrogens
-
Norpregnadienes
-
Progestins
-
etonogestrel
-
Desogestrel
-
nomegestrol acetate
-
Megestrol